1 / 4

Pipeline & HCV

Pipeline & HCV. UK-CAB 31 January 2009. Pipeline. TMC435 Hepatitis C Phase II-a, small cohorts, cohort 5. News @ EASL Phase II-b later in 2009 RSV353 (Respiratory Syncitial Virus) Phase I. Hepatitis C: Telaprevir. Co-development with VERTEX. Sponsored and managed by Vertex

iola
Download Presentation

Pipeline & HCV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pipeline & HCV UK-CAB 31 January 2009

  2. Pipeline • TMC435 Hepatitis C • Phase II-a, small cohorts, cohort 5. News @ EASL • Phase II-b later in 2009 • RSV353 (Respiratory Syncitial Virus) • Phase I

  3. Hepatitis C: Telaprevir. • Co-development with VERTEX. • Sponsored and managed by Vertex • 1050 Treatment-naïve patients. • Sponsored and managed by TIBOTEC • 650 Treatment-failure patients

  4. Studies for HIV/HCV coinfected patients • DDI studies ongoing. Tenofovir: no significant interaction • Coinfection study: pilot study will start this year • Synopsis of protocol has been sent to ECAB for review • US Community has seen and commented

More Related